BIO Comments on Promoting the Use of Complex Innovative Designs in Clinical Trials
March 20, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) public meeting on Promoting the Use of Complex Innovative Designs in Clinical Trials.
BIO supports the development and launch of this initiative. BIO shares the FDA’s goals for the pilot program to promote public learning about Innovative Clinical Trial Design (ICTD) and to demonstrate the use of novel designs to increase the efficiency and/or feasibility of clinical development. The pilot program will present multiple opportunities for public learning and the advancement of ICTD.
To advance the successful implementation of the ICTD Pilot Program, BIO developed recommendations on the timelines, communication, and disclosure of information, among other issues. BIO’s comments also include high-level case studies of innovative clinical trial designs which have historically shown low levels of regulatory, in an effort to provide insight into the general types of innovative clinical trial designs BIO would like to see in the pilot program.
One thing that we can all agree on is the need to give our children a fighting chance so they can lead long and productive lives. That is why it is critical to pass the bipartisan Give Kids a Chance Act and ensure the Pediatric Priority Review…
Dear Colleagues, This month marks my one-year anniversary as BIO's CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
BIO submitted comments on the Food and Drug Administration’s (FDA) public meeting on Promoting the Use of Complex Innovative Designs in Clinical Trials.
BIO supports the development and launch of this initiative. BIO shares the FDA’s goals for the pilot program to promote public learning about Innovative Clinical Trial Design (ICTD) and to demonstrate the use of novel designs to increase the efficiency and/or feasibility of clinical development. The pilot program will present multiple opportunities for public learning and the advancement of ICTD.
To advance the successful implementation of the ICTD Pilot Program, BIO developed recommendations on the timelines, communication, and disclosure of information, among other issues. BIO’s comments also include high-level case studies of innovative clinical trial designs which have historically shown low levels of regulatory, in an effort to provide insight into the general types of innovative clinical trial designs BIO would like to see in the pilot program.